Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...
OXFORD, England, Jan. 6, 2026 /PRNewswire/ -- Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been ...
The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...
Pharmaceutical Technology on MSN
Amgen buys Dark Blue Therapeutics in $840m oncology deal
According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...
The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...
In what is thought to be the first major pharma M&A deal of the year, Amgen has bought Oxford, UK-based biotech Dark Blue ...
ABSTRACT: The effects of tributyltin (TBT) and dibutyltin (DBT) on the hemocyte functions of the blue mussel Mytilus edulis were investigated in 2 separate experiments at 2 different cold periods of ...
California healthcare innovator Amgen, which already has facilities at Cambridge Science Park, has made a new and incisive acquisition in the UK - buying Oxford University spin-out Dark Blue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback